BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pagola-Lorz I, Vicente E, Ibáñez B, Torné L, Elizalde-Beiras I, Garcia-Solaesa V, García F, Delfrade J, Jericó I. Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis 2019;14:276. [PMID: 31791368 DOI: 10.1186/s13023-019-1227-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang K, Bi FF, Yang H. A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy. Front Neurol 2021;12:761636. [PMID: 34795634 DOI: 10.3389/fneur.2021.761636] [Reference Citation Analysis]
2 Bazrafshan S, Kushlaf H, Kakroo M, Quinlan J, Becker RC, Sadayappan S. Genetic Modifiers of Hereditary Neuromuscular Disorders and Cardiomyopathy. Cells 2021;10:349. [PMID: 33567613 DOI: 10.3390/cells10020349] [Reference Citation Analysis]
3 Flabeau O, Bisson T. [Multidisciplinary care of patients with Myotonic Dystrophy type 1 (DM1) in South Aquitaine]. Med Sci (Paris) 2021;37 Hors série n° 1:32-5. [PMID: 34878392 DOI: 10.1051/medsci/2021190] [Reference Citation Analysis]
4 Nicolau S, Milone M, Liewluck T. Guidelines for genetic testing of muscle and neuromuscular junction disorders. Muscle Nerve 2021;64:255-69. [PMID: 34133031 DOI: 10.1002/mus.27337] [Reference Citation Analysis]
5 Schiava M, Marchesoni C, García de Rosa M, Estrada N, Cejas L, Pardal A, Pirra L, Repetto L, Torres A, Dubrovsky A, Reisin R. Genetic characterization of Limb Girdle Muscular Dystrophies and Pompe Disease in a large Argentine cohort. Neurology Perspectives 2022. [DOI: 10.1016/j.neurop.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Müller KI, Ghelue MV, Lund I, Jonsrud C, Arntzen KA. The prevalence of hereditary neuromuscular disorders in Northern Norway. Brain Behav 2021;11:e01948. [PMID: 33185984 DOI: 10.1002/brb3.1948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Jericó I, Elizalde-Beiras I, Pagola I, Torné L, Galbete A, Delfrade-Osinaga J, Vicente E. Clinical features and incidence trends of amyotrophic lateral sclerosis in Navarre, Spain, 2007-2018: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener 2021;22:401-9. [PMID: 33641502 DOI: 10.1080/21678421.2021.1891249] [Reference Citation Analysis]
8 Vicente E, Pruneda L, Ardanaz E. Paradoja de la rareza: a propósito del porcentaje de población afectada por enfermedades raras. Gaceta Sanitaria 2020;34:536-8. [DOI: 10.1016/j.gaceta.2020.02.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sánchez Marín JP, Sienes Bailo P, Lahoz Alonso R, Capablo Liesa JL, Gazulla Abio J, Giménez Muñoz JA, Modrego Pardo PJ, Pardiñas Barón B, Izquierdo Álvarez S. Myotonic dystrophy type1: 13years of experience at a tertiary hospital. Clinical and epidemiological study and genotype-phenotype correlation. Neurologia (Engl Ed) 2021:S0213-4853(21)00050-5. [PMID: 33972121 DOI: 10.1016/j.nrl.2021.02.012] [Reference Citation Analysis]
10 Llamosas-Falcón L, Sánchez-Díaz G, Gallego E, Villaverde-Hueso A, Arias-Merino G, Posada de la Paz M, Alonso-Ferreira V. A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain. Sci Rep 2022;12:3750. [PMID: 35260676 DOI: 10.1038/s41598-022-07814-z] [Reference Citation Analysis]